GlassScriptPhysician profile
Irfan Kundi
NPI 1366504128
$3,867.28
in general payments reported to CMS, 2019-2025
27 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $71.42 · 2021: $97.95 · 2022: $639 · 2023: $750 · 2024: $873 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675 · Education: $34.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.97 |
| Education | $34.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $367.77 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $320.11 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $291.17 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $278.35 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Astrazeneca Pharmaceuticals LP | $267.88 | 2019-2024 | Lokelma, Farxiga |
| Amgen INC. | $251.51 | 2020-2025 | Tavneos, Krystexxa |
| Merck Sharp & Dohme LLC | $215.84 | 2023-2025 | Prevymis, Zerbaxa |
| Vifor Pharma, INC. | $196.26 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.42 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $182.87 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $158.23 | 2019-2023 | Rayaldee |
| Bayer Healthcare Pharmaceuticals INC. | $148.06 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $147.30 | 2022-2024 | Terlivaz, Acthar |
| Veloxis Pharmaceuticals, INC. | $133.75 | 2019-2025 | Envarsus |
| Ardelyx, INC. | $130.27 | 2024-2025 | Ibsrela |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $127.32 | 2019-2023 | Ultomiris |
| Horizon Therapeutics Plc | $99.39 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $71.82 | 2022-2025 | Purified Cortrophin Gel |
| Cormedix INC. | $71.61 | 2024-2025 | Defencath, Defencath |
| Novo Nordisk INC | $56.48 | 2025 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $32.43 | 2022 | |
| Daiichi Sankyo INC. | $29.59 | 2022 | |
| Apellis Pharmaceuticals, INC. | $24.95 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $24.08 | 2023 | Lupkynis |
| Lilly USA, LLC | $21.44 | 2025 | Zepbound, Mounjaro |
| Azurity Pharmaceuticals, INC. | $15.58 | 2025 | Edarbi |
| Mallinckrodt Enterprises LLC | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Kundi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.